Medindia

X

Pharmazz, Inc. advances its product pipeline for the treatment of stroke, strengthens patent portfolio and presents hemorrhagic shock data at the American Heart Association

Wednesday, November 30, 2016 Heart Disease News J E 4
Advertisement
- A human study has been initiated to determine the safety and tolerance of PMZ-1620

NAPERVILLE, Ill., Nov. 30, 2016 /PRNewswire/ -- Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. Results of the human safety and pharmacokinetics of PMZ-2010 were presented at the American Heart Association Scientific Sessions 2016. Abstract titled "Human pharmacokinetics of centhaquin citrate, a novel resuscitative agent" and "Centhaquin citrate improves cerebral blood flow and reduces oxidative stress following hemorrhagic shock in rats" were presented. Pharmazz is developing PMZ-2010 (centhaquin) as a resuscitative agent having a unique property of increasing blood pressure and cardiac output, and decreasing vascular resistance in hemorrhagic shock. In addition, the company is developing PMZ-1620 which is a neuroregenerative agent that produces neurogenesis and angiogenesis in the damaged area of the brain by stimulating endogenous regenerative mechanisms. A human study (CTRI/2016/11/007509) has been initiated to determine the safety and tolerance of PMZ-1620. The company also announced that a Notice of Issuance was received from the US Patent and Trademark Office, for the patent application regarding "Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist" United States Patent No. 9,493,524 issued on November 15th 2016. In addition, the company declared issuance of patent titled "Method and composition for treating diabetic ketoacidosis" by Canadian Intellectual Property Office on November 29th 2016. In patients with diabetic ketoacidosis high levels of ketone can be dangerously harmful to the body; PMZ-2123 when used with insulin can rapidly lower the blood ketone levels.

"We are pleased to have been granted these Notice of Issuance from the US and Canadian Patent Office," said Dr. Anil Gulati, Inventor and founder of Pharmazz. He added that, "Advancing PMZ-1620 towards human studies is a significant step for the company to develop a novel product that will provide a new simple option for the treatment of patients with (stroke) cerebral ischemia."

About Pharmazz, Inc.  Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.  

Forward-Looking Statements  This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact  Pharmazz, Inc.   Shruti Gulati  630-780-6087  shruti.gulati@pharmazz.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmazz-inc-advances-its-product-pipeline-for-the-treatment-of-stroke-strengthens-patent-portfolio-and-presents-hemorrhagic-shock-data-at-the-american-heart-association-300370066.html

SOURCE Pharmazz, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Biosurgery Market Worth 27.78 Billion USD by 2021
S
Prix Galien Russia Committee to Distinguish Five S...